Biotechnology

With new backing from specialist fund SCI Ventures, ViaNautis is deploying its novel gene delivery platform to develop regenerative therapies for paralysis.

With a massive cash infusion and novel brain-delivery tech, newly public Korsana Biosciences is betting it can succeed where many have failed in neurodegeneration.

With a key conference appearance, OPKO Health aims to translate its deep R&D pipeline into market confidence. Will investors buy into its long-term vision?

With new patents in Australia and Japan, Leveragen isn't just protecting its tech. It's building a data-rich biological engine for AI-driven medicine.

The Vancouver biotech is advancing a dual-targeting CAR and a safer STING therapy, betting that precision and strategy will pave its path to NASDAQ and beyond.

Encoded Therapeutics' ETX101 shows potential to not only halt seizures but also reverse developmental delays, suggesting a paradigm shift for rare neurological disorders.

Newly restructured Niki BioSolutions faces Wall Street at a key conference, pitching its brain health innovations while battling steep losses and investor doubt.

New AI-powered analysis of Endeavor BioMedicines' taladegib shows significant lung volume gains, offering a glimmer of hope for reversing damage in IPF.

With a $70M boost and backing from Eli Lilly, Moonwalk Biosciences aims to redefine obesity treatment by targeting fat tissue directly, not appetite.

As BioVie seeks FDA approval for a pivotal Phase 3 trial, its novel anti-inflammatory drug could usher in a new era for Parkinson's patients.

As Neurogene prepares for a key investor conference, all eyes are on its lead candidate for Rett syndrome. The company bets its proprietary EXACT™ technology can solve a critical gene therapy challenge, holding immense promise for patients and investors alike.

Alterome Therapeutics brings on a heavy-hitting CFO in Johanna Mylet, who guided Poseida to an IPO and Roche acquisition. What does this signal for its future?

A $39.2M federal grant isn't just funding a project; it's signaling a revolution to move genetic medicine manufacturing from massive plants to bedside boxes.

While we focus on breakthrough drugs, the real story is often in the logistics. GCCL’s expansion into Asia-Pacific highlights the critical, and lucrative, world of clinical trial support.

Intellia Therapeutics secures a massive non-dilutive debt facility from OrbiMed, a strategic move to fund its one-time CRISPR therapy for HAE.

A breakthrough in proteomics allows Nautilus Biotechnology to map individual disease-linked proteins, promising to revolutionize diagnostics and drug discovery.

A landmark bill in Congress and nationwide walks aim to channel millions into R&D for a genetic disorder affecting 500,000 Americans, creating a new roadmap for a cure.

With over a billion in the bank, Spyre Therapeutics is hitting the investor circuit. But cash is only half the story. Can upcoming data validate its ambitious strategy?

A small biotech is making a bold leap, leveraging its heart disease expertise to tackle Alzheimer's and Parkinson's with a novel class of brain drugs.

Cipla and Qilu are teaming up to launch a biosimilar for Keytruda, the world's top cancer drug, signaling a major shift in patient access and market dynamics.